Prognostic significance of monocarboxylate transporter expression in oral cavity tumors

Cell Cycle

Volumn 15, Issue 14, 2016, Pages 1865-1873

  Simões Sousa, Susana ^a,b   Granja, Sara ^a,b   Pinheiro, Céline ^a,b,c,d   Fernandes, Daniela ^a,b   Longatto Filho, Adhemar ^a,b,d,e   Laus, Ana Carolina ^d   Alves, Cira Danielle Casado ^d   Suarez Penaranda J M ^f   Pérez Sayáns, Mario ^g   Lopes Carvalho, Andre ^d   Schmitt, Fernando C ^h,i,j   García García, Abel ^g   Baltazar, Fatima ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c Paulo Prata Faculty of Health Sciences   (Brazil)

^d BARRETOS CANCER HOSPITAL   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

^g UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^h UNIVERSITY OF PORTO   (Portugal)

ⁱ University of Porto   (Portugal)

^j LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

more..

Author keywords

aerobic glycolysis; head and neck cancer; lactate transport; monocarboxylate transporters

Indexed keywords

CD147 ANTIGEN; GLUCOSE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 2; MONOCARBOXYLATE TRANSPORTER 4; MONOCARBOXYLATE TRANSPORTER;

ADULT; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL MEMBRANE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENDER; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH TUMOR; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MOUTH; PATHOLOGY; PROGNOSIS;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; MOUTH; MOUTH NEOPLASMS; PROGNOSIS;

EID: 84976299772     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2016.1188239     Document Type: Article

References (62)

1. S.I.Pai, W.H.Westra. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 2009; 4:49-70; PMID:18729723; http://dx.doi.org/10.1146/annurev.pathol.4.110807.092158
2. R.Siegel, J.Ma, Z.Zou, A.Jemal. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
3. A.Argiris, M.V.Karamouzis, D.Raben, R.L.Ferris. Head and neck cancer. Lancet 2008; 371:1695-709; PMID:18486742; http://dx.doi.org/10.1016/S0140-6736(08)60728-X
4. R.Feldman, Z.Gatalica, J.Knezetic, S.Reddy, C.A.Nathan, N.Javadi, T.Teknos. Molecular profiling of head and neck squamous cell carcinoma. Head Neck 2015; PMID:26614708
5. S.B.Chinn, J.N.Myers. Oral Cavity Carcinoma: Current Management, Controversies, and Future Directions. J Clin Oncol 2015; 33:3269-76; PMID:26351335; http://dx.doi.org/10.1200/JCO.2015.61.2929
6. Y.H.Ni, L.Ding, Q.G.Hu, Z.C.Hua. Potential biomarkers for oral squamous cell carcinoma: proteomics discovery and clinical validation. Proteomics Clin Appl 2015; 9:86-97; PMID:25431113; http://dx.doi.org/10.1002/prca.201400091
7. M.Upadhyay, J.Samal, M.Kandpal, O.V.Singh, P.Vivekanandan. The Warburg effect: insights from the past decade. Pharmacol Ther 2013; 137:318-30; PMID:23159371; http://dx.doi.org/10.1016/j.pharmthera.2012.11.003
8. R.J.Deberardinis, N.Sayed, D.Ditsworth, C.B.Thompson. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18:54-61; PMID:18387799; http://dx.doi.org/10.1016/j.gde.2008.02.003
9. J.P.Bayley, P.Devilee. The Warburg effect in 2012. Curr Opin Oncol 2012; 24:62-7; PMID:22123234; http://dx.doi.org/10.1097/CCO.0b013e32834deb9e
10. W.Sun, Y.Liu, C.A.Glazer, C.Shao, S.Bhan, S.Demokan, M.Zhao, M.A.Rudek, P.K.Ha, J.A.Califano. TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res 2010; 16:857-66; PMID:20103683; http://dx.doi.org/10.1158/1078-0432.CCR-09-2604
11. E.C.Nakajima, C.Laymon, M.Oborski, W.Hou, L.Wang, J.R.Grandis, R.L.Ferris, J.M.Mountz, B.Van Houten. Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions. PLoS One 2014; 9:e102452; PMID:25127378; http://dx.doi.org/10.1371/journal.pone.0102452
12. D.M.Brizel, T.Schroeder, R.L.Scher, S.Walenta, R.W.Clough, M.W.Dewhirst, W.Mueller-Klieser. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51:349-53; PMID:11567808; http://dx.doi.org/10.1016/S0360-3016(01)01630-3
13. S.Walenta, T.Schroeder, W.Mueller-Klieser. Metabolic mapping with bioluminescence: basic and clinical relevance. Biomol Eng 2002; 18:249-62; PMID:11841946; http://dx.doi.org/10.1016/S1389-0344(01)00107-1
14. P.Tripathi, P.Kamarajan, B.S.Somashekar, N.MacKinnon, A.M.Chinnaiyan, Y.L.Kapila, T.M.Rajendiran, A.Ramamoorthy. Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target. Int J Biochem Cell Biol 2012; 44:1852-61; PMID:22743333; http://dx.doi.org/10.1016/j.biocel.2012.06.025
15. F.Hirschhaeuser, U.G.Sattler, W.Mueller-Klieser. Lactate: a metabolic key player in cancer. Cancer Res 2011; 71:6921-5; PMID:22084445; http://dx.doi.org/10.1158/0008-5472.CAN-11-1457
16. G.Kroemer, J.Pouyssegur. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13:472-82; PMID:18538731; http://dx.doi.org/10.1016/j.ccr.2008.05.005
17. A.B.Haugrud, Y.Zhuang, J.D.Coppock, W.K.Miskimins. Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells. Breast Cancer Res Treat 2014; 147:539-50; PMID:25212175; http://dx.doi.org/10.1007/s10549-014-3128-y
18. A.P.Halestrap. The SLC16 gene family - structure, role and regulation in health and disease. Mol Aspects Med 2013; 34:337-49; PMID:23506875; http://dx.doi.org/10.1016/j.mam.2012.05.003
19. J.Adijanto, N.J.Philp. The SLC16A family of monocarboxylate transporters (MCTs)–physiology and function in cellular metabolism, pH homeostasis, and fluid transport. Curr Top Membr 2012; 70:275-311; PMID:23177990; http://dx.doi.org/10.1016/B978-0-12-394316-3.00009-0
20. C.Pinheiro, A.Longatto-Filho, J.Azevedo-Silva, M.Casal, F.C.Schmitt, F.Baltazar. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012; 44:127-39; PMID:22407107; http://dx.doi.org/10.1007/s10863-012-9428-1
21. F.Baltazar, C.Pinheiro, F.Morais-Santos, J.Azevedo-Silva, O.Queiros, A.Preto, M.Casal. Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol Histopathol 2014; 29(12):1511-24. Epub 2014 Jun 12
22. P.Kirk, M.C.Wilson, C.Heddle, M.H.Brown, A.N.Barclay, A.P.Halestrap. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. Embo j 2000; 19:3896-904; PMID:10921872; http://dx.doi.org/10.1093/emboj/19.15.3896
23. C.Pinheiro, A.Longatto-Filho, S.M.Pereira, D.Etlinger, M.A.Moreira, L.F.Jube, G.S.Queiroz, F.Schmitt, F.Baltazar. Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. Dis Markers 2009; 26:97-103; PMID:19597291; http://dx.doi.org/10.1155/2009/169678
24. S.M.Gallagher, J.J.Castorino, D.Wang, N.J.Philp. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 2007; 67:4182-9; PMID:17483329; http://dx.doi.org/10.1158/0008-5472.CAN-06-3184
25. J.Zhu, Y.N.Wu, W.Zhang, X.M.Zhang, X.Ding, H.Q.Li, M.Geng, Z.Q.Xie, H.M.Wu. Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients. PLoS One 2014; 9:e87904; PMID:24498219; http://dx.doi.org/10.1371/journal.pone.0087904
26. L.Szablewski. Expression of glucose transporters in cancers. Biochim Biophys Acta 2013; 1835:164-9; PMID:23266512
27. M.Perez-Sayans, C.T.Supuran, S.Pastorekova, J.M.Suarez-Penaranda, G.D.Pilar, F.Barros-Angueira, J.M.Gandara-Rey, A.Garcia-Garcia. The role of carbonic anhydrase IX in hypoxia control in OSCC. J Oral Pathol Med 2013; 42:1-8; PMID:22417164; http://dx.doi.org/10.1111/j.1600-0714.2012.01144.x
28. F.R.Ayala, R.M.Rocha, K.C.Carvalho, A.L.Carvalho, I.W.da Cunha, S.V.Lourenco, F.A.Soares. GLUT1 and GLUT3 as potential prognostic markers for Oral Squamous Cell Carcinoma. Molecules 2010; 15:2374-87; PMID:20428049; http://dx.doi.org/10.3390/molecules15042374
29. C.Pinheiro, A.Longatto-Filho, C.Scapulatempo, L.Ferreira, S.Martins, L.Pellerin, M.Rodrigues, V.A.Alves, F.Schmitt, F.Baltazar. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch 2008; 452:139-46; PMID:18188595; http://dx.doi.org/10.1007/s00428-007-0558-5
30. C.Pinheiro, B.Sousa, A.Albergaria, J.Paredes, R.Dufloth, D.Vieira, F.Schmitt, F.Baltazar. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 2011; 26:1279-86; PMID:21870331
31. V.Miranda-Goncalves, M.Honavar, C.Pinheiro, O.Martinho, M.M.Pires, C.Pinheiro, M.Cordeiro, G.Bebiano, P.Costa, I.Palmeirim, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol 2013; 15:172-88; PMID:23258846; http://dx.doi.org/10.1093/neuonc/nos298
32. S.Granja, F.Morais-Santos, V.Miranda-Goncalves, M.Viana-Ferreira, R.Nogueira, C.Nogueira-Silva, J.Correia-Pinto, F.Baltazar. The monocarboxylate transporter inhibitor alpha-cyano-4-hydroxycinnamic acid disrupts rat lung branching. Cell Physiol Biochem 2013; 32:1845-56; PMID:24356196; http://dx.doi.org/10.1159/000356617
33. D.Hanahan, R.A.Weinberg. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
34. C.Pinheiro, S.Granja, A.Longatto-Filho, A.M.Faria, M.C.Fragoso, S.M.Lovisolo, A.M.Lerario, M.Q.Almeida, F.Baltazar, M.C.Zerbini. Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors. Oncotarget 2015; 29;6(42):44403-21. http://dx.doi.org/10.18632/oncotarget.5623.
35. C.Pinheiro, E.A.Garcia, F.Morais-Santos, M.A.Moreira, F.M.Almeida, L.F.Jube, G.S.Queiroz, E.C.Paula, M.A.Andreoli, L.L.Villa, et al. Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas. BMC Cancer 2015; 15:835; PMID:26525902; http://dx.doi.org/10.1186/s12885-015-1842-4
36. L.Sweeny, N.R.Dean, J.W.Frederick, J.S.Magnuson, W.R.Carroll, R.A.Desmond, E.L.Rosenthal. CD147 expression in advanced cutaneous squamous cell carcinoma. J Cutan Pathol 2012; 39:603-9; PMID:22575025; http://dx.doi.org/10.1111/j.1600-0560.2012.01912.x
37. H.Stegeman, S.E.Rademakers, P.N.Span, R.P.Takes, A.J.van der Kogel, J.H.Kaanders, J.Bussink. Hypoxia, metabolism, and growth factor signaling in head and neck squamous cell carcinoma: correlation between primary and xenograft tumors. Head Neck 2014; 36:1288-95; PMID:24668936
38. S.E.Rademakers, J.Lok, A.J.van der Kogel, J.Bussink, J.H.Kaanders. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 2011; 11:167; PMID:21569415; http://dx.doi.org/10.1186/1471-2407-11-167
39. K.C.Carvalho, I.W.Cunha, R.M.Rocha, F.R.Ayala, M.M.Cajaiba, M.D.Begnami, R.S.Vilela, G.R.Paiva, R.G.Andrade, F.A.Soares. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) 2011; 66:965-72; PMID:21808860; http://dx.doi.org/10.1590/S1807-59322011000600008
40. D.E.Burstein, C.Nagi, D.S.Kohtz, L.Lee, B.Wang. Immunodetection of GLUT1, p63 and phospho-histone H1 in invasive head and neck squamous carcinoma: correlation of immunohistochemical staining patterns with keratinization. Histopathology 2006; 48:717-22; PMID:16681688; http://dx.doi.org/10.1111/j.1365-2559.2006.02408.x
41. F.Siddiqui, M.Yao. Application of fluorodeoxyglucose positron emission tomography in the management of head and neck cancers. World J Radiol 2014; 6:238-51; PMID:24976927; http://dx.doi.org/10.4329/wjr.v6.i6.238
42. E.Majchrzak, W.Cholewinski, W.Golusinski. Carcinoma of unknown primary in the head and neck: The evaluation of the effectiveness of (18)F-FDG-PET/CT, own experience. Rep Pract Oncol Radiother 2015; 20:393-7; PMID:26549998; http://dx.doi.org/10.1016/j.rpor.2015.07.002
43. Y.Yokobori, M.Toyoda, K.Sakakura, K.Kaira, Y.Tsushima, K.Chikamatsu. (18)F-FDG uptake on PET correlates with biological potential in early oral squamous cell carcinoma. Acta Otolaryngol 2015; 135:494-9; PMID:25739639; http://dx.doi.org/10.3109/00016489.2014.969385
44. V.A.Alves, C.Pinheiro, F.Morais-Santos, A.Felipe-Silva, A.Longatto-Filho, F.Baltazar. Characterization of monocarboxylate transporter activity in hepatocellular carcinoma. World J Gastroenterol 2014; 20:11780-7; PMID:25206282; http://dx.doi.org/10.3748/wjg.v20.i33.11780
45. R.Le Floch, J.Chiche, I.Marchiq, T.Naiken, K.Ilc, C.M.Murray, S.E.Critchlow, D.Roux, M.P.Simon, J.Pouyssegur. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A 2011; 108:16663-8; PMID:21930917; http://dx.doi.org/10.1073/pnas.1106123108
46. C.Pinheiro, R.M.Reis, S.Ricardo, A.Longatto-Filho, F.Schmitt, F.Baltazar. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol 2010; 2010:427694; PMID:20454640; http://dx.doi.org/10.1155/2010/427694
47. I.M.Sara Granja, R.Le FlochRenaud, C.Souto MouraConceição, F.BaltazarFátima, J.PouysségurJacques. Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status. Oncotarget 2014.
48. N.Pertega-Gomes, J.R.Vizcaino, V.Miranda-Goncalves, C.Pinheiro, J.Silva, H.Pereira, P.Monteiro, R.M.Henrique, R.M.Reis, C.Lopes, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 2011; 11:312; PMID:21787388; http://dx.doi.org/10.1186/1471-2407-11-312
49. A.Ohno, K.Yorita, Y.Haruyama, K.Kondo, A.Kato, T.Ohtomo, M.Kawaguchi, K.Marutuska, K.Chijiiwa, H.Kataoka. Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma. Liver Int 2014; 34:942-52; PMID:24433439; http://dx.doi.org/10.1111/liv.12466
50. H.Izumi, M.Takahashi, H.Uramoto, Y.Nakayama, T.Oyama, K.Y.Wang, Y.Sasaguri, S.Nishizawa, K.Kohno. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci 2011; 102:1007-13; PMID:21306479; http://dx.doi.org/10.1111/j.1349-7006.2011.01908.x
51. G.Baek, Y.F.Tse, Z.Hu, D.Cox, N.Buboltz, P.McCue, C.J.Yeo, M.A.White, R.J.DeBerardinis, E.S.Knudsen, et al. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep 2014; 9:2233-49; PMID:25497091; http://dx.doi.org/10.1016/j.celrep.2014.11.025
52. N.Vigneswaran, S.Beckers, S.Waigel, J.Mensah, J.Wu, J.Mo, K.E.Fleisher, J.Bouquot, P.G.Sacks, W.Zacharias. Increased EMMPRIN (CD 147) expression during oral carcinogenesis. Exp Mol Pathol 2006; 80:147-59; PMID:16310185; http://dx.doi.org/10.1016/j.yexmp.2005.09.011
53. L.S.Monteiro, M.L.Delgado, S.Ricardo, F.Garcez, B.do Amaral, J.J.Pacheco, C.Lopes, H.Bousbaa. EMMPRIN expression in oral squamous cell carcinomas: correlation with tumor proliferation and patient survival. 2014; 2014:905680; PMID:24967412
54. D.Dang, A.Atakilit, D.M.Ramos. EMMPRIN modulates migration and deposition of TN-C in oral squamous carcinoma. Anticancer Res 2008; 28:2049-54; PMID:18751374
55. A.Siu, J.Chang, C.Lee, S.Lee, C.Lee, D.M.Ramos. Expression of EMMPRIN modulates mediators of tumor invasion in oral squamous cell carcinoma. J Calif Dent Assoc 2013; 41:831-8; PMID:24341135
56. Z.Huang, N.Tan, W.Guo, L.Wang, H.Li, T.Zhang, X.Liu, Q.Xu, J.Li, Z.Guo. Overexpression of EMMPRIN isoform 2 is associated with head and neck cancer metastasis. PLoS One 2014; 9:e91596; http://dx.doi.org/10.1371/annotation/c85feb29-046d-45f6-ba12-510f9e1d9412
57. Z.Huang, L.Wang, Y.Wang, Y.Zhuo, H.Li, J.Chen, W.Chen. Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells. J Oral Pathol Med 2013; 42:541-6; PMID:23413783; http://dx.doi.org/10.1111/jop.12046
58. Y.H.Yu, J.Morales, L.Feng, J.J.Lee, A.K.El-Naggar, N.Vigneswaran. CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 119:553-65; PMID:25747176; http://dx.doi.org/10.1016/j.oooo.2014.12.022
59. V.C.Angadi, P.V.Angadi. GLUT-1 immunoexpression in oral epithelial dysplasia, oral squamous cell carcinoma, and verrucous carcinoma. J Oral Sci 2015; 57:115-22; PMID:26062860; http://dx.doi.org/10.2334/josnusd.57.115
60. J.S.Yang, C.W.Lin, C.Y.Chuang, S.C.Su, S.H.Lin, S.F.Yang. Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma. Tumour Biol 2015; 36:9517-24; PMID:26130414; http://dx.doi.org/10.1007/s13277-015-3692-8
61. A.C.Klimowicz, P.Bose, S.K.Petrillo, A.M.Magliocco, J.C.Dort, N.T.Brockton. The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma. Br J Cancer 2013; 109:1859-66; PMID:24008660; http://dx.doi.org/10.1038/bjc.2013.533
62. A.W.Eckert, M.Kappler, J.Schubert, H.Taubert. Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients. Oral Maxillofac Surg 2012; 16:189-96; PMID:22592457; http://dx.doi.org/10.1007/s10006-012-0335-8